Gemcitabine-induced heparanase promotes aggressiveness of pancreatic cancer cells via activating EGFR signaling.

about

Gemcitabine-induced heparanase promotes aggressiveness of pancreatic cancer cells via activating EGFR signaling.

Item

http://www.wikidata.org/entity/Q41709484

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Gemcitabine-induced heparanase ...... via activating EGFR signaling.

@en

type

Item

label

Gemcitabine-induced heparanase ...... via activating EGFR signaling.

@en

prefLabel

Gemcitabine-induced heparanase ...... via activating EGFR signaling.

@en

P1476

Gemcitabine-induced heparanase ...... via activating EGFR signaling

@en

P2093

Feng Gong

http://www.w3.org/2001/XMLSchema#string

Hong Zhou

http://www.w3.org/2001/XMLSchema#string

Lu-Ming Wan

http://www.w3.org/2001/XMLSchema#string

Shi-Kun Zhang

http://www.w3.org/2001/XMLSchema#string

Shou-Ping Ji

http://www.w3.org/2001/XMLSchema#string

Su-Bo Li

http://www.w3.org/2001/XMLSchema#string

Ying-Xia Tan

http://www.w3.org/2001/XMLSchema#string

Zhi-Hang Zhou

http://www.w3.org/2001/XMLSchema#string

P2860

Heparanase expression in primary and metastatic pancreatic cancer

5-fluorouracil: mechanisms of action and clinical strategies

Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts

Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer

EGF receptor is required for KRAS-induced pancreatic tumorigenesis

M402, a novel heparan sulfate mimetic, targets multiple pathways implicated in tumor progression and metastasis

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

Small RNA interference-mediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells

Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer.

Shed Syndecan-1 is involved in chemotherapy resistance via the EGFR pathway in colorectal cancer

P304

58417-58429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.16911

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jin-Wen Song

P577

2017-04-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28938567

http://www.w3.org/2001/XMLSchema#string

P932

5601663

http://www.w3.org/2001/XMLSchema#string